Acute Promyelocytic Leukemia (DBCOND0036178)

Identifiers

Synonyms

Acute Promyelocytic Leukemia (APL) / Acute promyelocytic leukemia / Leukemia, Promyelocytic, Acute / Acute promyelocytic leukaemia / Acute promyelocytic leukemia, not having achieved remission / Disorder: Acute promyelocytic leukemia, FAB M3 (disorder) / Acute promyelocytic leukemia with PML::RARA fusion (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Arsenic trioxide	A chemotherapeutic agent used in the treatment of refractory or relapsed acute promyelocytic leukemia in patients with prior retinoid and anthracycline chemotherapy.	Inhibitor of nuclear factor kappa-B kinase subunit betatarget Transcription factor Juntarget G1/S-specific cyclin-D1target Mitogen-activated protein kinase 3target Mitogen-activated protein kinase 1target RAC-alpha serine/threonine-protein kinasetarget ATP-binding cassette sub-family C member 2transporter Thioredoxin reductase 1, cytoplasmictarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Cyclin-dependent kinase inhibitor 1target Histone deacetylase 1target Protein PMLtarget Albumincarrier
Cytarabine	A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.	DNA polymerase betatarget Cytidine deaminaseenzyme Solute carrier family 22 member 4transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Cytochrome P450 3A4enzyme Deoxycytidine kinaseenzyme 5'-nucleotidaseenzyme Deoxycytidylate deaminaseenzyme DNA polymerase catalytic subunittarget
Mercaptopurine	An antineoplastic agent used to treat acute lymphocytic leukemia.	Thiopurine S-methyltransferaseenzyme Xanthine dehydrogenase/oxidaseenzyme Hypoxanthine-guanine phosphoribosyltransferasetarget Organic anion transporter 3transporter ATP-binding cassette sub-family C member 4transporter ATP-binding cassette sub-family C member 5transporter Sodium/nucleoside cotransporter 2transporter Solute carrier family 28 member 3transporter Equilibrative nucleoside transporter 1transporter Equilibrative nucleoside transporter 2transporter Aldehyde oxidaseenzyme Amidophosphoribosyltransferasetarget Inosine-5'-monophosphate dehydrogenasetarget Inosine-5'-monophosphate dehydrogenase 1target
Methotrexate	An antineoplastic agent used the treatment of a wide variety of cancers as well as severe psoriasis, severe rheumatoid arthritis, and juvenile rheumatoid arthritis.	Dihydrofolate reductasetarget Aldehyde oxidaseenzyme Methylenetetrahydrofolate reductase (NADPH)enzyme Albumincarrier ATP-binding cassette sub-family C member 3transporter ATP-binding cassette sub-family C member 4transporter Multidrug resistance-associated protein 1transporter Solute carrier family 22 member 6transporter ATP-binding cassette sub-family C member 10transporter Organic anion transporter 3transporter ATP-binding cassette sub-family C member 2transporter ATP-dependent translocase ABCB1transporter Solute carrier organic anion transporter family member 1A2transporter Monocarboxylate transporter 1transporter ATP-binding cassette sub-family C member 11transporter Solute carrier organic anion transporter family member 1B3transporter Solute carrier family 22 member 11transporter Solute carrier organic anion transporter family member 1C1transporter Solute carrier organic anion transporter family member 3A1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 7transporter Solute carrier organic anion transporter family member 1B1transporter 6-phosphogluconate dehydrogenase, decarboxylatingenzyme Proton-coupled folate transportertransporter Folylpolyglutamate synthase, mitochondrialenzyme Gamma-glutamyl hydrolaseenzyme Dihydrofolate reductaseenzyme Thymidylate synthaseenzyme Bifunctional purine biosynthesis protein ATICenzyme Solute carrier organic anion transporter family member 4C1transporter Reduced folate transportertransporter Folate receptor alphatransporter Cytochrome P450 3A4enzyme Thymidylate synthasetarget Bifunctional purine biosynthesis protein ATICtarget Folate receptor betatransporter Solute carrier family 15 member 1transporter Proton-coupled amino acid transporter 1transporter Carboxypeptidase G2enzyme Proton-coupled folate transportertarget Reduced folate transportertarget
Mitoxantrone	A chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis.	DNA topoisomerase 2-alphatarget Cytochrome P450 2E1enzyme ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter DNAtarget Cytochrome P450 1B1enzyme Cytochrome P450 3A4enzyme DNA topoisomerase 2-betatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01463410	Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler	No drug interventions	Not Available	Not Available	terminated
NCT02086773	Red Cell Transfusion Goals in Patients With Acute Leukemias	No drug interventions	supportive_care	1	completed
NCT00185523	Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)	No drug interventions	Not Available	Not Available	terminated
NCT02390752	Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...	Pexidartinib	treatment	1	recruiting
NCT00504764	Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)	Arsenic trioxide Tretinoin	treatment	4	completed
NCT04175587	Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL	Arsenic trioxide Indigo Tetraarsenic tetrasulfide Tretinoin	treatment	3	unknown_status
NCT00465933	Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)	No drug interventions	treatment	4	completed
NCT02309333	Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database	No drug interventions	Not Available	Not Available	terminated
NCT00875745	Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)	Sorafenib Vorinostat	treatment	1	completed
NCT01987297	Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL	Arsenic trioxide Cytarabine Daunorubicin Idarubicin Tretinoin	treatment	4	unknown_status
NCT00003861	Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT00180128	AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia	Cytarabine Daunorubicin Idarubicin Mitoxantrone	prevention	4	unknown_status
NCT01472107	Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy	No drug interventions	Not Available	Not Available	completed
NCT00852709	Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Clofarabine Cyclophosphamide	treatment	1	terminated
NCT00599937	APL93: Timing of CxT and Role of Maintenance	No drug interventions	treatment	3	completed
NCT00675870	Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia	Gelatin IRX-5183	treatment	2	unknown_status
NCT01404949	Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy	Arsenic trioxide Tretinoin	treatment	2	completed
NCT03096496	Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy	No drug interventions	Not Available	Not Available	unknown_status
NCT02938858	French Registry of First-line Treatment of Acute Promyelocytic Leukemia	No drug interventions	Not Available	Not Available	unknown_status
NCT02991066	Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia	No drug interventions	Not Available	Not Available	unknown_status
NCT00413166	All-trans Retinoic Acid, and Arsenic +/- Idarubicin	Arsenic trioxide Gemtuzumab ozogamicin Idarubicin Tretinoin	treatment	2	completed
NCT05832320	Optimum Induction Therapy of Low-risk APL	Daunorubicin Etoposide Indigo Tetraarsenic tetrasulfide Tretinoin	treatment	Not Available	recruiting
NCT00907582	ASCT for Relapsed APL After Molecular Remission	No drug interventions	treatment	2	terminated
NCT01334060	WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation	No drug interventions	treatment	2	completed
NCT02899169	Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)	Arsenic trioxide Hydroxyurea Indigo Tetraarsenic tetrasulfide Tretinoin	treatment	3	unknown_status
NCT00520208	Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL	Tamibarotene	treatment	2	completed
NCT01226303	Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia	No drug interventions	treatment	3	unknown_status
NCT04251754	The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project	No drug interventions	Not Available	Not Available	recruiting
NCT00408278	Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)	Cytarabine Idarubicin Mitoxantrone	treatment	4	completed
NCT06544109	Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients	Venetoclax	prevention	2 / 3	enrolling_by_invitation
NCT03624270	Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia	Arsenic trioxide Ascorbic acid	treatment	2	recruiting
NCT01064570	AIDA 2000 Guidelines	Tretinoin	treatment	2	unknown_status
NCT04562818	Results From a Mexican Acute Promyelocytic Leukemia.	No drug interventions	Not Available	Not Available	completed
NCT04793919	Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia	Arsenic trioxide Gemtuzumab ozogamicin Tretinoin	treatment	2	recruiting
NCT03751917	Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia	Arsenic trioxide	Not Available	Not Available	recruiting
NCT00985530	Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia	Arsenic trioxide Tamibarotene	treatment	1	terminated
NCT04996030	A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia	Arsenic trioxide	treatment	1	suspended
NCT00591526	A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)	Cytarabine	treatment	3	completed
NCT00378365	Acute Promyelocytic Leukemia 2006 (APL)	No drug interventions	treatment	3	unknown_status
NCT04687176	Frontline Oral Arsenic Trioxide for APL	Arsenic trioxide Ascorbic acid Tretinoin	treatment	2	recruiting
NCT01902329	A Safety Study of SGN-CD33A in AML Patients	Vadastuximab talirine	treatment	1	completed
NCT02688140	Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia	Arsenic trioxide Cytarabine Idarubicin Mercaptopurine Methotrexate Mitoxantrone Tretinoin	treatment	3	active_not_recruiting
NCT00517712	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia	Arsenic trioxide	treatment	2 / 3	unknown_status
NCT00670150	New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia	Arsenic trioxide IRX-5183	treatment	2	withdrawn
NCT01910623	Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia	No drug interventions	Not Available	Not Available	completed